Got 90 seconds? Then listen to CEO and managing director, Dr Liz Dallimore tell us about their company news.

Argenica Therapeutics (ASX:AGN) is working towards the commercialisation of a novel neuroprotective therapeutic treatment – ARG-007 – to reduce the damaging effects of stroke and other acute CNS injuries.

There is currently a large unmet need for a safe, early intervention therapeutic that provides protection to brain cells immediately following a stroke, until the underlying cause of stroke can be diagnosed and alleviated.

Argenica intends for ARG-007 to be administered by first responders in the field to provide neuroprotective treatment prior to a patient’s arrival at the hospital which will result in improved patient outcomes.

We gave Dr Liz Dallimore, CEO and managing director of Argenica Therapeutics, 90 seconds to tell us more about their recent news.

Have a good idea for our next 90 Seconds With segment? Email us at [email protected].